CMTX-101

DRUG2 trials

Sponsors

Clarametyx Biosciences, Inc.

Conditions

Bacterial PneumoniaCommunity-acquired PneumoniaCystic FibrosisPersistent Infection

Phase 1

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

TerminatedNCT05629741

Clarametyx Biosciences, Inc.Bacterial Pneumonia, Community-acquired Pneumonia

Start: 2022-11-14End: 2024-08-02Updated: 2024-10-21

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

CompletedNCT06159725

Clarametyx Biosciences, Inc.Cystic Fibrosis, Persistent Infection

Start: 2024-06-24End: 2025-11-14Updated: 2026-05-05